ANI Pharmaceuticals (ANIP)
(Delayed Data from NSDQ)
$59.20 USD
+0.25 (0.42%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $59.32 +0.12 (0.20%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$59.20 USD
+0.25 (0.42%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $59.32 +0.12 (0.20%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth A Momentum A VGM
Zacks News
ANI Pharmaceuticals (ANIP) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
ANI (ANIP) delivered earnings and revenue surprises of 42.25% and 3.50%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate ANI Pharmaceuticals (ANIP) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
ANI (ANIP) delivered earnings and revenue surprises of 3.08% and 1.73%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate ANI Pharmaceuticals (ANIP) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for May 24th
by Zacks Equity Research
ANIP, BHVN, FVRR, KBAL, and PLNT have been added to the Zacks Rank #5 (Strong Sell) List on May 24, 2021
ANI Pharmaceuticals (ANIP) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
ANI (ANIP) delivered earnings and revenue surprises of 42.47% and 13.59%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: ANI Pharmaceuticals (ANIP) Q1 Earnings Expected to Decline
by Zacks Equity Research
ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ANI Pharmaceuticals (ANIP) Enters Overbought Territory
by Zacks Equity Research
ANI Pharmaceuticals (ANIP) has moved higher as of late, but there could definitely be trouble on the horizon for this company
ANI Pharmaceuticals (ANIP) Q4 Earnings Miss Estimates
by Zacks Equity Research
ANI (ANIP) delivered earnings and revenue surprises of -20.00% and 3.91%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: ANI Pharmaceuticals (ANIP) Q4 Earnings Expected to Decline
by Zacks Equity Research
ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should Value Investors Pick ANI Pharmaceuticals (ANIP) Now?
by Zacks Equity Research
Let's see if ANI Pharmaceuticals (ANIP) stock is a good choice for value-oriented investors right now from multiple angles.
Analysts Estimate ANI Pharmaceuticals (ANIP) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ANI Pharmaceuticals (ANIP) Q2 Earnings Miss Estimates
by Zacks Equity Research
ANI (ANIP) delivered earnings and revenue surprises of -2.82% and 6.06%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: ANI Pharmaceuticals (ANIP) Q2 Earnings Expected to Decline
by Zacks Equity Research
ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for July 8th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
ANI Pharmaceuticals (ANIP) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
ANI (ANIP) delivered earnings and revenue surprises of 16.85% and 0.76%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Are Investors Undervaluing ANI Pharmaceuticals (ANIP) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
AMAG Sees High Feraheme Sales, To Sell Women Healthcare Drugs
by Zacks Equity Research
AMAG (AMAG) plans to divest two of its women healthcare drugs, Intrarosa and Vyleesi. Its marketed drug, Feraheme, achieves record sales in 2019.
New Strong Sell Stocks for March 5th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
ANI Pharmaceuticals (ANIP) Q4 Earnings and Revenues Lag Estimates
by Zacks Equity Research
ANI (ANIP) delivered earnings and revenue surprises of -8.47% and -6.32%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
4 Drug/Biotech Outperformers That May Lose Steam in 2020
by Kinjel Shah
Here we discuss some biotech stocks, which are up this year so far but might not be good additions to your portfolio.
New Strong Sell Stocks for December 4th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Moving Average Crossover Alert: ANI Pharmaceuticals
by Zacks Equity Research
ANI Pharmaceuticals could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
ANI Pharmaceuticals (ANIP) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
ANI (ANIP) delivered earnings and revenue surprises of -16.89% and -10.25%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
ANI Pharmaceuticals (ANIP) to Report Q3 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.